Findings suggest path to targeted MS treatments
2 Sep 17 · 6d ago · 2 articles · 1 comment · 2 sources · development 2 of 2
The research identifies B cells and ABC-like B cells as key immune cells showing the strongest changes before relapse, with EBV proteins triggering MS risk genes. Senior author Chitnis notes the results point toward more precise therapeutic approaches targeting EBV or specific immune cells, rather than broad immune suppression.
“Currently, most MS treatments work by broadly suppressing the immune system. Our results suggest there's an opportunity to be more precise and develop approaches that target EBV or the immune cells involved in relapse.”
Tanuja Chitnis, MDTanuja Chitnis, MD Senior author, Mass General Brigham researcherMass General Brigham Research institution
The whole story articlespostscomments the bright band is this development · numbered dots are the others · click one to jump
Reported in the same hours no headline names this development itself — these 1 claim were published in its stretch
-
first by medicalxpress.com, 6d ago · also News-Medical
1 more headline
- Study illuminates the link between the Epstein-Barr virus and multiple sclerosis News-Medical · 6d ago
What people said 1 voice · verbatim
-
Hey man, It's ok. Don't feel too bad about it. AI is a tool best used for understanding and learning, and you did use it for that. You know more on this matter than I do, that's clear, because you knew what questions to ask. You are clearly active in the field, or at least invested in it, but bots so easily impersonate actual people. So one has…
All 2 developments of Mass General study links Epstein-Barr virus reactivation to… →
RedditGoogle News